Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
151-165 of 4468 results
Novartis partners with Conatus on new oral treatments for chronic liver diseases
By PBR Staff Writer
Swiss pharma giant Novartis is collaborating with US biotechnology firm Conatus Pharmaceuticals on the development of new oral treatments for chronic liver diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Celgene partner to identify neurodegenerative disease candidates
Evotec and Celgene have entered into a drug discovery and development collaboration to identify disease-modifying therapeutics for a range of neurodegenerative diseases.
Drug Research > Drug Discovery & Development > News
Novartis to acquire Ziarco to expand dermatology portfolio
Novartis has agreed to acquire Ziarco Group, a privately held firm engaged in the development of novel treatments in dermatology.
Drug Research > Drug Discovery & Development > News
Lonza agrees to acquire Capsugel for $5.5bn
By PBR Staff Writer
Swiss pharmaceutical firm Lonza has agreed to acquire US drug capsules manufacturer Capsugel from Kohlberg Kravis Roberts (KKR) for $5.5bn in cash.
Drug Research > Drug Discovery & Development > News
Third Rock launches Goldfinch Bio for kidney disease work
Third Rock Ventures has launched Goldfinch Bio, a company focused on the discovery and development of precision therapies for patients with kidney disease.
Drug Research > Drug Discovery & Development > News
Bayer, Versant Ventures invest $225m in new stem cell therapy company
By PBR Staff Writer
Bayer and health care investment firm Versant Ventures are investing $225m in a new stem cell therapy company, BlueRock Therapeutics.
Drug Research > Drug Discovery & Development > News
Forge Therapeutics, Evotec establish superbug alliance
Forge Therapeutics has partnered with Evotec to advance its novel Gram-negative antibiotic program targeting ‘LpxC’ to treat bacterial infections including those caused by drug resistant superbugs.
Drug Research > Drug Discovery & Development > News
Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration
By PBR Staff Writer
Bicycle Therapeutics and AstraZeneca have agreed a $1bn multi-target collaboration across respiratory, cardiovascular and metabolic diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Merck sign deals to partner on target discovery technologies
Evotec and Merck have signed agreements to collaborate on target discovery technologies.
Drug Research > Drug Discovery & Development > News
OxThera raises EUR32m to complete Oxabact development to treat primary hyperoxaluria
Swedish privately-held biopharmaceutical firm OxThera has raised EUR32m to complete development of Oxabact for the treatment of primary hyperoxaluria.
Drug Research > Drug Discovery & Development > News
Ergomed acquires PharmInvent
Pharmaceutical services and drug development firm Ergomed has acquired European PharmInvent Services s.r.o. (PharmInvent), a European pharmacovigilance and regulatory services business.
Drug Research > Drug Discovery & Development > News
UK biopharmaceutical firm Kymab secures $100m of funding
By PBR Staff Writer
UK-based biopharmaceutical firm Kymab has secured $100m of funding to advance its pipeline of therapeutic human monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
WuXi Biologics, Prima sign non-binding MOU for biologics development
WuXi Biologics, a WuXi AppTec group company, and Prima Biomed have signed a non-binding MOU to form a strategic biologics development and manufacturing partnership.
Drug Research > Drug Discovery & Development > News
Allergan acquires Chase Pharmaceuticals
Allergan has acquired Chase Pharmaceuticals, a clinical-stage biopharmaceutical firm engaged in the development of improved treatments for neurodegenerative disorders including Alzheimer's disease (AD).
Drug Research > Drug Discovery & Development > News
FDA scientists develop new mouse model for Zika studies
Scientists at the US Food and Drug Administration (FDA) have developed a new mouse model which may help in exploring the potential activity of Zika virus vaccines and therapeutics.
Drug Research > Drug Discovery & Development > News
151-165 of 4468 results